Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis

Key facts

Sponsor

Assistance Publique - Hôpitaux de Paris

Principal Investigator

Xavier PUECHAL, PhD, NPC

Hôpital Cochin, Assistance Publique-Hôpitaux de Paris - Service de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques "

Intervention

Obinutuzumab(drug)

Enrollment

33 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2028

Study locations (1)

• Service de Médecine Interne, Centre de reference "Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques", Paris, France

Collaborators

URC-CIC Paris Descartes Necker Cochin

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Granulomatosis with polyangiitis

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03919435
  TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
  University of Pennsylvania
• ACTIVE NOT RECRUITINGPHASE3NCT01933724
  The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
  University of South Florida

See all trials for Granulomatosis with polyangiitis →